Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TARGETING DUAL PATHWAYS IN REFRACTORY COCCYDYNIA: A COMPARATIVE STUDY OF GANGLION IMPAR BLOCK ALONE VERSUS COMBINED WITH PERICOCCYGEAL INJECTION

NCT07060313 is registered in ClinicalTrials.gov with Istanbul University as lead sponsor.

NCT NCT07060313
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07060313 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TARGETING DUAL PATHWAYS IN REFRACTORY COCCYDYNIA: A COMPARATIVE STUDY OF GANGLION IMPAR BLOCK ALONE VERSUS COMBINED WITH PERICOCCYGEAL INJECTION
Lead sponsor
Istanbul University
Phase
Phase 3
Overall status
Completed
Start date
June 1, 2022
Completion date
June 2, 2024
Enrollment
60 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

coccydynia